6MWT	6 min walk test
AF	Atrial fibrillation
AFL	Atrial flutter
CAD	Coronary artery disease
CKD	Chronic kidney disease
CVD	Cardiovascular disease
DAPA-HF	Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure
DECLARE–TIMI 58	Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58
DM	Diabetes mellitus
DDP4	Dipeptidylpeptidase 4
eGFR	Estimated glomerular filtration rate
EMA	European Medicines Agency
EMPA-REG OUTCOME	Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose
FDA	Food and Drug Administration
GLP-1 RAs	Glucagon-like peptide-1 receptor agonists
HF	Heart failure
HFE	Heart failure event
HFrEF	Heart failure with reduced ejection fraction
LVEDV	Left ventricular end-diastolic volume
LVEF	Left ventricular ejection fraction
LVESD	Left ventricular end-systolic diameter
LVESV	Left ventricular end-systolic volume
MACE	Major adverse cardiovascular events
NYHA	New York Heart Association
SBP	Systolic blood pressure
SGLT2	Sodium/glucose cotransporter 2
T2DM	Type 2 diabetes mellitus